The European Medicines Agency has started reviewing a new batch of drugs, including aprocitentan and sugemalimab, for potential pan-EU marketing authorization.
Aprocitentan is Idorsia/Janssen Biotech’s novel dual endothelin receptor antagonist for the treatment of patients with resistant hypertension.








